Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Behcet Disease - Overview
Behcet Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Behcet Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Behcet Disease - Companies Involved in Therapeutics Development
Amgen Inc
GlaxoSmithKline Plc
Iltoo Pharma
InSight Biopharmaceuticals Ltd
Novartis AG
Pharmapraxis
R Pharm
Silk Road Therapeutics
Behcet Disease - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1070806 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentoxifylline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Behcet Disease - Dormant Projects
Behcet Disease - Discontinued Products
Behcet Disease - Product Development Milestones
Featured News & Press Releases
Feb 27, 2020: CHMP recommended extensions of indication for Otezla
Jul 19, 2019: FDA approves OTEZLA (apremilast) for the treatment of oral ulcers associatd with Behcet’s Disease
Feb 17, 2018: OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behcet’s Disease with Oral Ulcers
Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir
Mar 23, 2016: Turkish sigture on the biomolecules study - Hurriyet
Apr 15, 2015: Phase II Data for Apremilast in Beh?et’s Disease Published in The New England Jourl of Medicine
Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Beh?et’s Disease At EULAR
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Behcet Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Behcet Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Behcet Disease - Pipeline by Amgen Inc, H1 2020
Behcet Disease - Pipeline by GlaxoSmithKline Plc, H1 2020
Behcet Disease - Pipeline by Iltoo Pharma, H1 2020
Behcet Disease - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
Behcet Disease - Pipeline by Novartis AG, H1 2020
Behcet Disease - Pipeline by Pharmapraxis, H1 2020
Behcet Disease - Pipeline by R Pharm, H1 2020
Behcet Disease - Pipeline by Silk Road Therapeutics, H1 2020
Behcet Disease - Dormant Projects, H1 2020
Behcet Disease - Discontinued Products, H1 2020